To combat these alternative sellers, pharmaceutical company Eli Lilly began offering an alternative version of its brand-name Zepbound product for weight loss in September 2024. Instead of its ...

Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ...

Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound were no longer in shortage after nearly two years. Pharmacies that sold unbranded ...

For weight loss, you're more likely to have your insurance plan pay for Zepbound, which has the same main ingredient as Mounjaro. The difference is that Mounjaro is for diabetes and Zepbound is for ...

Surging demand for weight loss drugs Wegovy and Zepbound from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) has fueled concerns over a significant risk linked to the popular drug class: loss of ...

Under this 5-year trial deal, the US pharmaceutical giant will try to understand how tirzepatide — the GLP-1 treatment behind its Zepbound and Mounjaro drugs — impacts weight loss, diabetes ...

weight-loss industries. Yet despite the ubiquitousness of injectable drugs indicated for people with obesity—such as Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

To combat these alternative sellers, pharmaceutical company Eli Lilly began offering an alternative version of its brand-name Zepbound product for weight loss in September 2024. Instead of its ...